Diabetes medicines are an important part of the pharmaceutical industry, with multiple formulations developed to help manage blood glucose levels through different mechanisms. These medicines work by improving insulin sensitivity, stimulating insulin secretion, reducing glucose production or helping the body regulate glucose more effectively.
For pharmaceutical distributors and entrepreneurs, understanding these medicine categories is useful when exploring a Diabetic PCD Pharma Franchise. Knowledge of different antidiabetic formulations helps businesses evaluate product portfolios, understand market requirements and select a pharmaceutical company that offers relevant products.
Arlak Corazon offers a range of diabetic formulations, including single-molecule medicines and combination tablets covering several major antidiabetic categories. This article explores the types of diabetes medicines available in its portfolio, their mechanisms of action and their relevance to the diabetic pharma franchise segment.
Diabetes medicines are classified according to their active ingredients and how they work in the body. Different medicines target different aspects of glucose regulation, and some formulations combine multiple active ingredients to provide complementary mechanisms of action.
The diabetic medicine categories portfolio should include:
Biguanides – Metformin
Sulfonylureas – Glimepiride
DPP-4 inhibitors – Teneligliptin, Vildagliptin, Sitagliptin and Linagliptin
SGLT2 inhibitors – Dapagliflozin and Empagliflozin
Alpha-glucosidase inhibitors – Voglibose
Thiazolidinediones – Pioglitazone
Combination formulations containing multiple antidiabetic ingredients, including Repaglinide-based combinations
Metformin belongs to the biguanide class of oral antidiabetic medicines and is widely used in the management of type 2 diabetes.
Metformin primarily reduces glucose production in the liver and improves insulin sensitivity. It helps the body use insulin more effectively, contributing to better blood glucose regulation.
Metformin is commonly prescribed for type 2 diabetes. Depending on individual treatment requirements, it may be used as a single-ingredient medicine or in combination with other antidiabetic drugs.
ZULIP-500 SR – Metformin
ZULIP-1000 SR – Metformin
ZULIP-G1 – Glimepiride + Metformin
ZULIP-G2 – Glimepiride + Metformin
ZULIP-G1 FORTE – Glimepiride + Metformin
ZULIP-G2 FORTE – Glimepiride + Metformin
Metformin is also included in other combination formulations within Arlak Corazon's diabetic range.
Sulfonylureas are oral antidiabetic medicines that help lower blood glucose by stimulating insulin secretion from the pancreas.
Glimepiride stimulates pancreatic beta cells to release insulin. The increased availability of insulin helps lower blood glucose levels.
Glimepiride is used in type 2 diabetes, either as a single medicine or in combination with other antidiabetic formulations, when considered appropriate by the treating doctor.
COPRIDE-2 – Glimepiride 2 mg
COPRIDE-3 – Glimepiride 3 mg
COPRIDE-4 – Glimepiride 4 mg
ZULIP-G1 – Glimepiride + Metformin
ZULIP-G2 – Glimepiride + Metformin
ZULIP-G1 FORTE – Glimepiride + Metformin
ZULIP-G2 FORTE – Glimepiride + Metformin
ZULIP-GP1 – Glimepiride + Metformin + Pioglitazone
ZULIP-GP2 – Glimepiride + Metformin + Pioglitazone
This category includes both single-molecule and combination formulations within the company's diabetic portfolio.
DPP-4 inhibitors are oral antidiabetic medicines that work through the incretin hormone pathway, which plays a role in regulating insulin and glucagon secretion.
These medicines inhibit the DPP-4 enzyme responsible for breaking down incretin hormones. This helps support glucose-dependent insulin secretion and reduces glucagon release when blood glucose is elevated.
Teneligliptin
Vildagliptin
Sitagliptin
Linagliptin
TENETIN-20 – Teneligliptin
TENETIN-M – Teneligliptin + Metformin
TENETIN-M FORTE – Teneligliptin + Metformin
TENETIN-P – Teneligliptin + Pioglitazone
Z-VIL-50 – Vildagliptin
Z-VIL-M – Vildagliptin + Metformin
Z-VIL-M FORTE – Vildagliptin + Metformin
Z-VIL-P – Vildagliptin + Pioglitazone
SITAWAR-M – Sitagliptin + Metformin
SITAWAR-M FORTE – Sitagliptin + Metformin
LINAWISE-M – Linagliptin + Metformin
DPP-4 inhibitors represent an important part of the oral antidiabetic segment, with multiple molecules and combination formulations available.
SGLT2 inhibitors work through the kidneys and help lower blood glucose by increasing glucose excretion through urine.
These medicines reduce the reabsorption of glucose in the kidneys. As a result, more glucose is eliminated through urine, helping lower glucose levels in the bloodstream.
Dapagliflozin
Empagliflozin
DEPAZIDE-5 – Dapagliflozin
DEPAZIDE-10 – Dapagliflozin
DEPAZIDE-10M – Dapagliflozin + Metformin
EMPAWISH-10 – Empagliflozin
EMPAWISH-25 – Empagliflozin
SITAWAR-D – Dapagliflozin + Sitagliptin
SITAWAR-DM – Sitagliptin + Metformin + Dapagliflozin
SITAWAR-DM FORTE – Sitagliptin + Metformin + Dapagliflozin
SGLT2 inhibitor formulations are an important part of the modern antidiabetic market, with certain medicines in this category also used for specific cardiovascular and kidney indications.
Voglibose belongs to the alpha-glucosidase inhibitor category, which helps manage the rise in blood glucose after meals.
Voglibose slows the breakdown and absorption of carbohydrates in the intestine. This delays the entry of glucose into the bloodstream and helps reduce post-meal blood glucose elevations.
Voglibose is used in the management of type 2 diabetes, particularly for postprandial glucose control. It may be prescribed alone or in combination with other antidiabetic medicines.
CORAVOG-0.2 – Voglibose 0.2 mg
CORAVOG-0.3 – Voglibose 0.3 mg
CORAVOG-0.2M – Metformin + Voglibose
CORAVOG-0.3M – Metformin + Voglibose
CORAVOG-R 0.2/0.5 – Voglibose + Repaglinide
CORAVOG-R 0.2/1 – Voglibose + Repaglinide
CORAVOG-GM1 – Glimepiride + Metformin + Voglibose
CORAVOG-GM3 – Glimepiride + Metformin + Voglibose
The CORAVOG range includes formulations with different combinations, bringing together medicines that act through different glucose-regulation mechanisms.
Pioglitazone belongs to the thiazolidinedione class of medicines, which helps improve insulin sensitivity in the body.
Pioglitazone acts on receptors involved in glucose and lipid metabolism, helping improve the body's response to insulin. This can contribute to better blood glucose regulation in selected patients with type 2 diabetes.
COGLIT-15 – Pioglitazone 15 mg
Z-VIL-P – Vildagliptin + Pioglitazone
TENETIN-P – Teneligliptin + Pioglitazone
ZULIP-GP1 – Glimepiride + Metformin + Pioglitazone
ZULIP-GP2 – Glimepiride + Metformin + Pioglitazone
Pioglitazone is represented in the company's range through both single-ingredient and combination formulations.
Combination antidiabetic medicines contain two or more active ingredients that work through different mechanisms. These formulations are developed to address different aspects of blood glucose regulation within a single dosage form.
Combinations by Arlak Corazon for Cardiac Diabetic PCD Pharma Franchise:
Metformin + Glimepiride
Metformin + Teneligliptin
Metformin + Vildagliptin
Metformin + Sitagliptin
Metformin + Dapagliflozin
Glimepiride + Metformin + Pioglitazone
Glimepiride + Metformin + Voglibose
Voglibose + Repaglinide
Sitagliptin + Metformin + Dapagliflozin
These combinations represent different approaches to glucose management, including improving insulin sensitivity, supporting insulin secretion, reducing glucose production and regulating carbohydrate absorption.
The availability of multiple combination formulations is relevant to distributors evaluating the breadth of a diabetic medicine portfolio.
| Category | Active ingredient | How it works |
|---|---|---|
| Biguanides | Metformin | Reduces liver glucose production and improves insulin sensitivity |
| Sulfonylureas | Glimepiride | Stimulates insulin secretion |
| DPP-4 inhibitors | Teneligliptin, Vildagliptin, Sitagliptin, Linagliptin | Supports incretin-mediated glucose regulation |
| SGLT2 inhibitors | Dapagliflozin, Empagliflozin | Increases glucose excretion through urine |
| Alpha-glucosidase inhibitors | Voglibose | Delays carbohydrate digestion and absorption |
| Thiazolidinediones | Pioglitazone | Improves insulin sensitivity |
| Combination formulations | Multiple antidiabetic ingredients | Combines different mechanisms of glucose regulation |
The diabetic pharmaceutical segment consists of different molecules, strengths, combinations and formulations. For distributors and pharma entrepreneurs, understanding these categories can help them evaluate a company's portfolio and develop better product knowledge.
When exploring a Diabetic PCD Pharma Franchise, businesses should consider:
Breadth of antidiabetic medicine categories
Availability of single-molecule products
Range of combination formulations
Product strengths and compositions
Documentation and regulatory compliance
Supply consistency and order requirements
Territory rights and commercial arrangements
Promotional and marketing support
A well-understood portfolio can make it easier for a franchise partner to plan product promotion, inventory and distribution based on local market requirements.
Arlak Corazon offers a dedicated cardiac and diabetic medicine portfolio for PCD Parma Franchise pharma business partners interested in these therapeutic segments.
Its diabetic range includes multiple formulations based on Metformin, Glimepiride, DPP-4 inhibitors, SGLT2 inhibitors, Voglibose and Pioglitazone, including various combination products.
For entrepreneurs and distributors looking to enter the diabetic pharma segment, this provides an opportunity to explore a focused product portfolio under a dedicated pharmaceutical division.
Before starting a franchise, prospective partners should evaluate product availability, territory arrangements, pricing, order requirements, promotional support and other commercial conditions.
A Diabetic PCD Pharma Franchise is best approached as a distribution business that requires product understanding, market development, regulatory compliance and a clear agreement with the pharmaceutical company.
Its listed diabetic formulations include Metformin, Glimepiride, DPP-4 inhibitors, SGLT2 inhibitors, Voglibose and Pioglitazone-based medicines, including combination products.
DPP-4 inhibitors help regulate blood glucose by supporting incretin hormone activity, which influences insulin secretion and glucagon regulation. They are used in the management of type 2 diabetes.
SGLT2 inhibitors reduce glucose reabsorption in the kidneys, allowing more glucose to be eliminated through urine and helping lower blood glucose levels.
Voglibose slows carbohydrate digestion and absorption in the intestine, helping reduce the rise in blood glucose after meals.
Yes. Its published range includes combinations such as Metformin with Glimepiride, DPP-4 inhibitors, Dapagliflozin, Pioglitazone and Voglibose, as well as other combinations listed in its catalogue.
It is a pharmaceutical distribution and marketing arrangement in which an authorised partner markets and distributes diabetic medicines within an agreed territory under the company's terms and conditions.
A broader portfolio across different antidiabetic categories allows business partners to evaluate more product options, strengths and combinations when developing their distribution business.
Diabetes medicines are divided into multiple categories based on how they help regulate blood glucose. Metformin, Glimepiride, DPP-4 inhibitors, SGLT2 inhibitors, Voglibose and Pioglitazone represent important antidiabetic categories within Arlak Corazon's published product range.
For pharmaceutical entrepreneurs and distributors, understanding these categories is an important step when exploring the Diabetic PCD Pharma Franchise segment. It helps build product awareness and supports more informed decisions when evaluating pharma franchise companies.
Arlak Corazon offers a range of diabetic formulations across these categories, providing an opportunity for businesses interested in developing their presence in the diabetic pharmaceutical market.
Disclaimer: This blog is intended for general educational and pharmaceutical business information. Medicines should only be used under the supervision of a qualified healthcare professional. Product compositions, availability and approved indications should be verified against the latest official catalogue and product documentation.